PPARG and metabolic dysfunction-associated steatotic liver disease: Several studies have indicated that in rodent models and MASLD patients, the hepatic expression of the PPARG is negatively correlated with liver fat content and disease severity, highlighting the crucial role of PPARG in the occurrence and progression of MASLD [46,47,48].